ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+29.31%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$219M
AUM Growth
+$219M
(+41%)
Cap. Flow
+$34.9M
Cap. Flow
% of AUM
15.92%
Top 10 Holdings %
Top 10 Hldgs %
56.75%
Holding
48
New
14
Increased
16
Reduced
3
Closed
15
Top Buys
| 1 |
Viatris
VTRS
|
$21.2M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$12.9M |
| 3 |
Biodesix
BDSX
|
$9.66M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$7.73M |
| 5 |
Codexis
CDXS
|
$6.95M |
Top Sells
| 1 |
Eledon Pharmaceuticals
ELDN
|
$15.5M |
| 2 |
Ascendis Pharma
ASND
|
$12.6M |
| 3 |
QuidelOrtho
QDEL
|
$8.63M |
| 4 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$8.56M |
| 5 |
Cytokinetics
CYTK
|
$7.37M |
Sector Composition
| 1 | Healthcare | 97.93% |
| 2 | Financials | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$12.3B
| $21.2M | 9.66% | +1,130,504 | New | +$21.2M |
|
|
SAGE
2
DELISTED
Sage Therapeutics
SAGE
| $15.7M | 7.17% | 181,650 +79,188 | +77% | +$6.85M |
|
|
3
Jazz Pharmaceuticals
JAZZ
$7.75B
| $14.8M | 6.76% | 89,889 +78,442 | +685% | +$12.9M |
|
4
Insulet
PODD
$23.9B
| $11.7M | 5.32% | 45,624 +4,477 | +11% | +$1.14M |
|
|
NSTG
5
DELISTED
NanoString Technologies, Inc.
NSTG
| $11.6M | 5.27% | 172,862 +11,609 | +7% | +$776K |
|
6
Kura Oncology
KURA
$686M
| $11.3M | 5.16% | 346,518 +146,034 | +73% | +$4.77M |
|
7
Guardant Health
GH
$8.41B
| $10.2M | 4.66% | 79,239 +10,376 | +15% | +$1.34M |
|
|
8
Biodesix
BDSX
$62.6M
| $9.66M | 4.4% | +478,985 | New | +$9.66M |
|
9
Standard BioTools
LAB
$481M
| $9.27M | 4.23% | 1,544,904 +566,746 | +58% | +$3.4M |
|
10
Arcus Biosciences
RCUS
$1.13B
| $9.05M | 4.12% | 348,408 +219,366 | +170% | +$5.69M |
|
|
ARNA
11
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $7.78M | 3.55% | 101,245 +7,937 | +9% | +$610K |
|
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.73M | 3.53% | +88,195 | New | +$7.73M |
|
|
13
Codexis
CDXS
$246M
| $6.95M | 3.17% | +318,492 | New | +$6.95M |
|
|
AVDL
14
Avadel Pharmaceuticals
AVDL
$1.43B
| $6.39M | 2.91% | 955,856 +435,026 | +84% | +$2.91M |
|
15
PMV Pharmaceuticals
PMVP
$74.2M
| $5.94M | 2.71% | 96,595 +71,703 | +288% | +$4.41M |
|
16
10x Genomics
TXG
$1.74B
| $5.32M | 2.43% | 37,587 -5,925 | -14% | -$839K |
|
|
BNR
17
Burning Rock Biotech
BNR
$93.6M
| $5.03M | 2.29% | 217,728 +366 | +0.2% | +$8.46K |
|
18
iTeos Therapeutics
ITOS
$449M
| $4.68M | 2.13% | 138,384 +80,633 | +140% | +$2.73M |
|
19
C4 Therapeutics
CCCC
$185M
| $4.62M | 2.1% | +139,343 | New | +$4.62M |
|
20
Fate Therapeutics
FATE
$120M
| $4.61M | 2.1% | 50,709 -62,657 | -55% | -$5.7M |
|
21
VistaGen Therapeutics
VTGN
$102M
| $4.35M | 1.98% | +2,239,803 | New | +$4.35M |
|
22
Galecto
GLTO
$4.21M
| $4.22M | 1.92% | +337,352 | New | +$4.22M |
|
|
ITCI
23
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.16M | 1.89% | +130,654 | New | +$4.16M |
|
|
BMY.RT
24
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $3.56M | 1.62% | 5,152,098 +3,591,771 | +230% | +$2.48M |
|
25
Sutro Biopharma
STRO
$72.7M
| $3.42M | 1.56% | +157,583 | New | +$3.42M |
|